Subtype
Digestive System Carcinoma
CI-CAN-00000812Explore in graph →
2,124 active trials27 approved drugs139 evidence items
- NCIt
- C96963
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00000812Explore in graph →
Clinical trials
7,545 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (885)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03448757 | Determination of Autonomic Responses to the Exposure of Low Energy Electromagnetic Fields With Frequency Modulation in Patients With Advanced Hepatocellular Carcinoma and Healthy Individuals. | unknown | N/A | 60 | Hospital Sirio-LibanesOTHER | 1 | Nov 22, 2023 | clinicaltrials |
| NCT06134973 | A Prospective Study on the Application of Liquid Biopsy in the Surveillance of High-risk Population of HCC. | unknown | — | 1,000 | Tianjin Third Central HospitalOTHER | 1 | Nov 22, 2023 |
| clinicaltrials |
| NCT05512520 | Concurrent Chemoradiotherapy for Stage IVB Esophageal Squamous Cell Carcinoma（EC-CRT-003）(EC-CRT-003) | unknown | Phase 2 | 126 | Sun Yat-sen UniversityOTHER | 1 | Nov 18, 2023 | clinicaltrials |
| NCT06134193 | Combination Therapy of HAIC, Surufatinib and Tislelizumab for Unresectable or Metastatic Biliary Tract Cancer | unknown | Phase 2 | 41 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 0 | Nov 18, 2023 | clinicaltrials |
| NCT06135649 | Dissecting the Pattern of Nodal Spread in Post-neoadjuvant Pancreatoduodenectomy | unknown | — | 850 | Universita di VeronaOTHER | 1 | Nov 18, 2023 | clinicaltrials |
| NCT04999332 | Perioperative Leucovorin, Oxaliplatin, Docetaxel and S-1 (LOTS) For Locally Advanced Gastric or Gastroesophageal Junction Cancer(LOTS) | unknown | Phase 2 | 58 | National Cheng-Kung University HospitalOTHER | 1 | Nov 15, 2023 | clinicaltrials |
| NCT06124001 | Clinical Study of VG161 Combined With Camrelizumab in Patients With Advanced Primary Hepatocellular Carcinoma | unknown | Phase 1 / Phase 2 | 36 | CNBG-Virogin Biotech (Shanghai) Ltd.INDUSTRY | 0 | Nov 15, 2023 | clinicaltrials |
| NCT05781958 | Cadonilimab Combined With Gem/Cis as First Line Therapy in Patients With Advanced ICC | unknown | Phase 2 | 64 | Shen FengOTHER | 1 | Nov 2, 2023 | clinicaltrials |
| NCT06115174 | Clinical Study Evaluating the Anticancer Effect of Pentoxiphylline in Patients With Metastatic Colorectal Cancer(CRC - PTX) | unknown | Phase 4 | 44 | Tanta UniversityOTHER | 0 | Nov 2, 2023 | clinicaltrials |
| NCT06111326 | BC3402 in Combination With Durvalumab in Patients With Advanced Hepatocellular Carcinoma | unknown | Phase 1 / Phase 2 | 83 | Biocity Biopharmaceutics Co., Ltd.INDUSTRY | 1 | Nov 1, 2023 | clinicaltrials |
| NCT06106750 | Endoscopic Scissors Cutting Nasobiliary Duct VS Bilateral Plastic Stent | unknown | N/A | 122 | First People's Hospital of HangzhouOTHER | 1 | Oct 30, 2023 | clinicaltrials |
| NCT06103890 | Dynamic ctDNA Monitoring in Neoadjuvant Therapy for Esophageal Squamous Cell Carcinoma(ctDNA) | unknown | — | 100 | Hebei Medical University Fourth HospitalOTHER | 1 | Oct 27, 2023 | clinicaltrials |
| NCT06101758 | Ultrasound Assessment of Sarcopenia in Patients With Chronic Liver Disease: the SARCOLIVER Study(SARCOLIVER) | unknown | N/A | 125 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Oct 26, 2023 | clinicaltrials |
| NCT06102746 | Clinical Study of Surufatinib Plus Sintilimab Combined With Chemotherapy in the Treatment of Advanced Gastric Neuroendocrine Carcinoma | unknown | — | 20 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Oct 26, 2023 | clinicaltrials |
| NCT06003673 | A Clinical Study of Tislelizumab Combined With TACE and Lenvatinib in the Neoadjuvant Treatment of Resectable HCC | unknown | Phase 4 | 20 | First Affiliated Hospital of Fujian Medical UniversityOTHER | 1 | Oct 24, 2023 | clinicaltrials |
| NCT05498597 | AMT-151 in Patients With Selected Advanced Solid Tumours | unknown | Phase 1 | 30 | Multitude Therapeutics Inc.INDUSTRY | 2 | Oct 19, 2023 | clinicaltrials |
| NCT06088459 | NWRD06 DNA Plasmid for HCC After Radical Resection | unknown | Phase 1 | 9 | Newish Technology (Beijing) Co., Ltd.INDUSTRY | 1 | Oct 18, 2023 | clinicaltrials |
| NCT04115527 | Should a Standard Lymphadenectomy Include the No. 16 Lymph Nodes for Patients With Pancreatic Head Adenocarcinoma. | unknown | N/A | 100 | Ruijin HospitalOTHER | 1 | Oct 17, 2023 | clinicaltrials |
| NCT05250843 | TACE/HAIC Combined With Lenvatinib and Sintilimab in Neoadjuvant Therapy for Intermediate-stage HCC | unknown | Phase 2 / Phase 3 | 90 | Third Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 1 | Oct 13, 2023 | clinicaltrials |
| NCT06081322 | A Study to Evaluate the Safety and Efficacy of PRRT With 177Lu-EB-FAPI in Patients With Advanced Cholopancreatic Tumors(CISPD-5) | unknown | Phase 1 | 29 | Zhejiang UniversityOTHER | 1 | Oct 13, 2023 | clinicaltrials |
| NCT06078657 | IBI110 Combined With Sintilimab in Second-line Advanced or Metastatic Esophageal Squamous Cell Carcinoma(ESCC) | unknown | Phase 2 | 46 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 1 | Oct 12, 2023 | clinicaltrials |
| NCT06080854 | AG Combined With Immunotherapy and SBRT in Patients With Potentially Resectable Pancreatic Cancer | unknown | Phase 2 | 108 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 1 | Oct 12, 2023 | clinicaltrials |
| NCT04303403 | Study of Trametinib and Ruxolitinib in Colorectal Cancer and Pancreatic Adenocarcinoma | unknown | Phase 1 | 48 | National Cancer Centre, SingaporeOTHER | 1 | Oct 11, 2023 | clinicaltrials |
| NCT04943406 | Peritoneal Lavage Liquid Biopsy in Patients With Gastric Cancer(LIQUID) | unknown | — | 150 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | Oct 6, 2023 | clinicaltrials |
| NCT06065592 | Exploring Cancer-Associated Thromboembolism Prognosis Biomarkers and Polymorphisms(CAT_PB) | unknown | Phase 1 | 500 | Lebanese UniversityOTHER | 1 | Oct 6, 2023 | clinicaltrials |
| NCT06070623 | Follow up After TACE by Elastography and Color Doppler. | unknown | — | 54 | Assiut UniversityOTHER | 0 | Oct 6, 2023 | clinicaltrials |
| NCT06042842 | The Value of circRNAs (hsa_circ_0004001) in Early Diagnosis of HCC | unknown | — | 102 | Assiut UniversityOTHER | 0 | Oct 4, 2023 | clinicaltrials |
| NCT06062706 | Robotic vs. Laparoscopic vs. Open Living Donor Hepatectomy | unknown | — | 3,448 | King Faisal Specialist Hospital & Research CenterOTHER | 1 | Oct 2, 2023 | clinicaltrials |
| NCT04033107 | High Dose Vitamin C Combined With Metformin in the Treatment of Malignant Tumors | unknown | Phase 2 | 30 | Zhongnan HospitalOTHER | 1 | Sep 28, 2023 | clinicaltrials |
| NCT05352646 | NewishT Cell Therapy for HCC With High Risk of Recurrence After Radical Resection | unknown | Phase 1 | 26 | Newish Technology (Beijing) Co., Ltd.INDUSTRY | 1 | Sep 28, 2023 | clinicaltrials |
| NCT06055166 | A Clinical Study of Chemoradiotherapy Sequential Fluzoparib in Pan-solid Tumors | unknown | Phase 2 | 120 | Chongqing University Cancer HospitalOTHER | 0 | Sep 26, 2023 | clinicaltrials |
| NCT06048289 | Prospective Observational Study to Predict the Response of Biliary Tract Tumors to Immunotherapy | unknown | — | 150 | Zhejiang Cancer HospitalOTHER | 1 | Sep 25, 2023 | clinicaltrials |
| NCT06050447 | Factors Affecting the Results of Treatment of Patients With Colorectal Cancer | unknown | — | 1,200 | Immanuel Kant Baltic Federal UniversityOTHER | 1 | Sep 22, 2023 | clinicaltrials |
| NCT05010434 | Sintilimab and Bevacizumab Combined With Radiotherapy for Advanced Hepatocellular Carcinoma | unknown | Phase 2 | 46 | Sun Yat-sen UniversityOTHER | 1 | Sep 21, 2023 | clinicaltrials |
| NCT06047990 | Endobiliary Percutaneous Cryobiopsy in Malignant Biliary Obstruction(BICRYOB) | unknown | N/A | 20 | Brno University HospitalOTHER | 1 | Sep 21, 2023 | clinicaltrials |
| NCT06039280 | Comparison of Dexamethasone and N Acetylcysteine (NAC) Versus N Acetylcysteine (NAC) Alone in the Prevention of Post Embolization Syndrome in Patients With Hepatocellular Carcinoma Following Transarterial Chemoembolization. | unknown | N/A | 150 | Institute of Liver and Biliary Sciences, IndiaOTHER | 1 | Sep 15, 2023 | clinicaltrials |
| NCT05992584 | Lenvatinib, Sintilimab Plus SIRT for Unresectable HCC | unknown | Phase 2 | 30 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Sep 14, 2023 | clinicaltrials |
| NCT06001567 | Avatrombopag for HCC Patients With Thrombocytopenia Who Intend to Undergo TACE and/or HAIC | unknown | Phase 2 | 30 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Sep 14, 2023 | clinicaltrials |
| NCT03447951 | A Study of PTS100 in Primary HCC Patients(OASES) | unknown | Phase 2 | 33 | Gongwin Biopharm Co., Ltd.INDUSTRY | 1 | Sep 13, 2023 | clinicaltrials |
| NCT05371873 | A Study of Chromosomal Abnormalities as a Predictor of Staging and Prognosis in Patients With Liver Cancer | unknown | — | 250 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Sep 13, 2023 | clinicaltrials |
| NCT05448222 | Effect of Sarcopenia on Hepatocellular Carcinoma(HCC) After Systemic Therapies | unknown | — | 300 | First Affiliated Hospital of Wenzhou Medical UniversityOTHER | 1 | Sep 13, 2023 | clinicaltrials |
| NCT06034977 | Phase 2 Study of ADI-PEG 20 Plus Lenvatinib Treatment in Subjects With Unresectable Hepatocellular Carcinoma | unknown | Phase 2 | 120 | Chang Gung Memorial HospitalOTHER | 1 | Sep 13, 2023 | clinicaltrials |
| NCT05990231 | Cadonilimab/Anlotinib in Locally Advanced or Relapsed/Metastatic ESCC Patients After Failure of PD-1 Combined With Platinum-containing Chemotherapy | unknown | Phase 2 | 35 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Sep 11, 2023 | clinicaltrials |
| NCT06031480 | Anlotinib and TQB2450 in Advanced Hepatocellular Carcinoma After Failure of Prior Immune Checkpoint Inhibitors(FAITH) | unknown | Phase 2 | 55 | Shanghai Zhongshan HospitalOTHER | 1 | Sep 11, 2023 | clinicaltrials |
| NCT06029829 | The Clinical Significance of Peripheral Blood T Lymphocyte PD-1 Expression and T Cell Subset Distribution. | unknown | Phase 2 | 60 | Xin-Hua XuOTHER | 1 | Sep 8, 2023 | clinicaltrials |
| NCT06023147 | A Real-world Study of the Short-term Efficacy and Safety of E-TACE in Patients With Hepatocellular Carcinoma (HCC) | unknown | N/A | 298 | Xuhua DuanOTHER | 1 | Sep 7, 2023 | clinicaltrials |
| NCT04852211 | Laparoscopic Versus Open Major Hepatectomy for HCC Hepatectomy for Hepatocellular Carcinoma(AP-LAPO) | unknown | N/A | 212 | Chinese University of Hong KongOTHER | 1 | Aug 31, 2023 | clinicaltrials |
| NCT06017141 | Inhalational or Intravenous Anesthesia During Surgery for Patients With Colon Cancer, VIVA Study | unknown | Phase 2 | 80 | University of Kansas Medical CenterOTHER | 1 | Aug 30, 2023 | clinicaltrials |
| NCT05681949 | Therapeutic Assistance and Decision-making Algorithms in Hepatobiliary Tumor Boards(ADBoard) | unknown | N/A | 1,200 | Charite University, Berlin, GermanyOTHER | 1 | Aug 24, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Nov 22, 2023source: clinicaltrials